MorphoSys launches $200 million US IPO in largest biotech listing in a decade

Shutterstock photo

MorphoSys, which is licensing antibodies to pharmas and developing its own therapy for lymphoma, announced terms for its US IPO on Monday.

The Planegg, Germany-based company plans to raise $200 million by offering 8.3 million ADSs at a price of $24.12, the as-converted price of its common stock on the Frankfurt Stock Exchange. At $24.12, MorphoSys would command a market value of $3.0 billion. That would make it the largest biotech to list in the US in the past 10 years.

MorphoSys was founded in 1992 and booked $67 million in revenue for the 12 months ended December 31, 2017. It plans to list on the Nasdaq under the symbol MOR. Goldman Sachs, J.P. Morgan and Leerink Partners are the joint bookrunners on the deal. It is expected to price during the week of April 16, 2018.

The article MorphoSys launches $200 million US IPO in largest biotech listing in a decade originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital


Research Brokers before you trade

Want to trade FX?